Showing 1211-1220 of 1484 results for "".
- Gilead’s Veklury Gains Conditional EU Approval for Treatment of COVID-19https://modernod.com/news/gileads-veklury-gains-conditional-eu-approval-for-treatment-of-covid-19/2477970/Gilead Sciences said Friday that the European Commission granted conditional approval to Veklury (remdesivir) for the treatment of SARS-CoV-2 infection. The company noted that the clearance, which was based on a rolling review that began in April, follows a
- SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophieshttps://modernod.com/news/sparingvision-receives-european-orphan-designation-for-its-drug-candidate-spvn06-dedicated-to-inherited-retinal-dystrophies/2477959/SparingVision announced the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies. The decision is based on a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
- Nicox Updates on Zerviate Progress in China and Expands the Countries of its Agreement with Ocumension Therapeuticshttps://modernod.com/news/nicox-updates-on-zerviate-progress-in-china-and-expands-the-countries-of-its-agreement-with-ocumension-therapeutics/2477370/Nicox SA announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Drug Rhokiinsahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-drug-rhokiinsa/2477111/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension. The marketing authorization a
- Glaukos Announces Global Licensing Agreement With Intratus, Maker of Noninvasive Drug Delivery Platformhttps://modernod.com/news/glaukos-announces-global-licensing-agreement-with-intratus/2476756/Glaukos announced that it has entered into a licensing agreement with privately held, early-stage life sciences company Intratus. Under terms of the deal, Intratus has granted Glaukos a global exclusive license to
- Staar Surgical Announces FDA Approval of the Visian Toric ICL for the Correction of Myopia with Astigmatismhttps://modernod.com/news/staar-surgical-announces-fda-approval-of-the-visian-toric-icl-for-the-correction-of-myopia-with-astigmatism/2479890/Staar Surgical announced that the FDA has granted approval of the PMA supplement for the Visian Toric ICL for the correction of myopia with astigmatism. This approval represents an expansion of the Implantable Collamer Lens (ICL) product line for the correction of refractive error in patie
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St